Results 81 to 90 of about 476,894 (337)

Evaluate the renal system damage caused by zoledronic acid: a comprehensive analysis of adverse events from FAERS

BMC Cancer
Background Zoledronic acid (ZA) is widely used for the treatment of osteolytic bone metastases in malignancies and osteoporosis, but it has been associated with renal impairment.
Zhaojun Wang, Xin Su, Donglei Shi, Li Wei   +3 more
doaj   +1 more source

Adverse event reporting and patient safety at a University Hospital: Mapping, correlating and associating events for a data-based patient risk management [PDF]

, 2016
BACKGROUND: Reporting adverse events (AE) with a bearing on patient safety is fundamentally important to the identification and mitigation of potential clinical risks.
Baldo, Vincenzo, Buja, Alessandra, Cacco, Rosaria Manola, Dario, Claudio, DE BATTISTI, Elisa, Ottolitri, Ketty, Saieva, ANNA MARIA, Vinelli, Angela   +7 more
core   +1 more source

Long non‐coding RNAs as therapeutic targets in head and neck squamous cell carcinoma and clinical application

FEBS Open Bio, EarlyView.
Long non‐coding RNAs (lncRNAs) occupy an abundant fraction of the eukaryotic transcriptome and an emerging area in cancer research. Regulation by lncRNAs is based on their subcellular localization in HNSCC. This cartoon shows the various functions of lncRNAs in HNSCC discussed in this review.
Ellen T. Tran, Ruchi A. Patel, Amogh Chariyamane, Ratna B. Ray   +3 more
wiley   +1 more source

Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)

Frontiers in Pharmacology
ObjectiveSapropterin dihydrochloride is the first drug for the therapy of phenylketonuria, which is a rare disease that occurs one of 10,000–15,000 newborns.
Jiahong Zhong, Xihui Yu, Zhuomiao Lin
doaj   +1 more source

Quality Improvement Conference: Effect of Patient Safety Intelligence Inservice Training on Resident PSI Entry [PDF]

, 2016
Hospital administrators rely heavily on incident reporting systems to capture adverse events. 13.5% of Medicare beneficiaries discharged in October 2008 experienced adverse events.
Derylo, Amanda, Fair, Joanna, Rider, Josh   +2 more
core   +1 more source

Knockout of the mitoribosome rescue factors Ict1 or Mtrfr is viable in zebrafish but not mice: compensatory mechanisms underlying each factor's loss

FEBS Open Bio, EarlyView.
Mitochondria contain two mitoribosome rescue factors, ICT1 and MTRFR (C12orf65). ICT1 also functions as a mitoribosomal protein in mice and humans, and its loss is lethal. Although Mtrfr knockout mice could not be generated, knockout zebrafish lines for ict1 and mtrfr were established.
Nobukazu Nameki, Chika Tomisawa, Soichiro Hoshino, Hidehiko Shimizu, Masashi Abe, Sho Arai, Kanako Kuwasako, Naoki Asakawa, Yusuke Inoue, Takuro Horii, Izuho Hatada, Masakatsu Watanabe   +11 more
wiley   +1 more source

Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system

Therapeutic Advances in Drug Safety
Background: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are targeted therapies designed to selectively block CDK4/6, crucial regulators of the cell cycle.
Jun Shen, Pingli Luo, Jianmei Xu
doaj   +1 more source

Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis. [PDF]

BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are one of the most commonly used drugs for type 2 diabetes mellitus. Clinical guidelines recommend GLP-1 RAs as an adjunct to diabetes therapy in patients with chronic kidney disease ...
Abagyan, Ruben, Joulfayan, Haroutyun, Makunts, Tigran   +2 more
core   +1 more source

Using electronic health records to support clinical trials: a report on stakeholder engagement for EHR4CR [PDF]

, 2015
Background. The conduct of clinical trials is increasingly challenging due to greater complexity and governance requirements as well as difficulties with recruitment and retention.
Dugas, Martin, Ford, Ian, Kalra, Dipak, Mccowan, Colin, Prokosch, Hans-Ulrich, Sullivan, Frank M., Szmigielski, Cezary A., Thomson, Elizabeth   +7 more
core   +6 more sources

Phenotyping Healthcare Use 2–3 Decades Before the First Multiple Sclerosis Demyelinating Event

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Phenotype hospital, physician, and emergency department (ED) visits by diagnoses and specialty up to 29 years pre‐multiple sclerosis (MS) onset versus a matched population without MS. Methods We identified people with MS (PwMS) using population‐based administrative data from Ontario, Canada (1991–2020).
Helen Tremlett, Karl Everett, Colleen J. Maxwell, Feng Zhu, Ayesha Asaf, Ping Li, Kyla A. McKay, Yinshan Zhao, Ruth Ann Marrie   +8 more
wiley   +1 more source